-
Mashup Score: 0Optimizing and Refining Immunotherapy in Breast Cancer - 1 year(s) ago
Despite a rocky start in breast cancer, immune checkpoint inhibitors (ICIs) have now made their way into clinical practice.1 As noted in the review article accompanying this commentary by Jacob et al2 titled Role of Immunotherapy in Breast Cancer, the journey in developing immunotherapy in breast cancer has been challenging. Indeed, we have observed mostly low response rates to single-agent ICIs,…
Source: JCO Oncology PracticeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Role of Immunotherapy in Breast Cancer - 1 year(s) ago
The advent of immunotherapy, particularly immune checkpoint inhibitors (ICIs), has revolutionized the treatment of solid tumor malignancies. In breast cancer, the most robust data to date for ICI exist for triple-negative breast cancer (TNBC). Preclinical studies suggested increased antitumoral immune response in patients with TNBC undergoing ICI treatment. Early clinical trials investigated the…
Source: JCO Oncology PracticeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#Immunotherapy in #BreastCancer review @SayaJacob3: ICIs have efficacy when combined with chemo in the tx of #TNBC but important questions remain including optimal partners for #ICI, duration, predictive biomarkers, and use for HR+ and HER2+ 👉 https://t.co/F48XRYYxkb #bcsm https://t.co/7N2Ew96L9C
-
-
Mashup Score: 0
PURPOSE: Patients with colorectal cancer (CRC) experience a range of physical and psychologic symptoms, and supportive care needs throughout the illness trajectory. We used patient-reported outcomes and administrative health data to describe symptom burden and supportive care needs during and after adjuvant treatment and determine factors associated with changes to symptom burden. METHODS: A…
Source: JCO Oncology PracticeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Longitudinal #PRO symptom burden & supportive care needs in pts w/ #CRCsm during and after adjuvant tx show sx severity was generally low & most sx remained stable or improved after tx, but certain pts were more likely to have severe/persistent sx. ➡️ https://t.co/dp0tMS4kg5 https://t.co/csgpWURMar
-
-
Mashup Score: 1
Purpose: The Conquer Cancer Foundation (CCF), the philanthropic arm of ASCO, is responsible for funding innovative clinical research. CCF wants to broaden its donor base instead of relying predominantly on health-care companies. Our Leadership Development Program (LDP) group was tasked with identifying potential donor sources and making recommendations to increase funding. Materials and Methods:…
Source: JCO Oncology PracticeCategories: Hem/Oncs, Latest HeadlinesTweet-
Competitive Funding Strategies for the @ConquerCancerFd of @ASCO [Nov 22, 2016] @GIcancerDoc Goel @DickersonAdrien @jvonroennmd @mtmdphd @AnneTsao2 @JCOOP_ASCO https://t.co/VELWFWwRjI #ASCOLDP
-
-
Mashup Score: 1Current Issues in the Management of Patients With Newly Diagnosed Advanced-Stage High-Grade Serous Carcinoma of the Ovary - 1 year(s) ago
Ovarian cancer is the most common cause of mortality in patients with gynecologic malignancies. Advanced-stage high-grade serous carcinoma accounts for most ovarian cancer cases. Current issues in the management of patients with newly diagnosed advanced-stage high-grade serous ovarian cancer include decisions on primary versus interval cytoreduction, hyperthermic intraperitoneal chemotherapy,…
Source: JCO Oncology PracticeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#HGSOC Review @DrCourtneyPenn: Evidence & guidelines for the management of pts with newly diagnosed advanced-stage high-grade serous #ovariancancer #HGSC including cytoreduction, #HIPEC, chemo, bevacizumab, genetic testing & #ParpI are discussed. https://t.co/1H4FH9OhDX https://t.co/pbgSE6b9cP
-
-
Mashup Score: 5Key Clinical Principles in the Management of Glioblastoma - 1 year(s) ago
Glioblastoma is the most common and aggressive primary brain tumor in the adult population and leads to considerable morbidity and mortality. It has a dismal prognosis with average survival of 15-18 months, and the current standard-of-care treatment paradigm includes maximal surgical resection and postoperative concurrent chemoradiotherapy and maintenance chemotherapy, with consideration of Tumor…
Source: JCO Oncology PracticeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
RT @jamecancerdoc: Key Clinical Principles in the Management of Glioblastoma @JCOOP_ASCO @ASCO https://t.co/0MifiJ5K8k Excellent review by…
-
-
Mashup Score: 1
PURPOSE: Numerous biologic drugs will soon be facing biosimilar competition. We study the case of trastuzumab, a revolutionary drug approved in 1998 to treat human epidermal growth factor receptor 2–positive breast cancer, to understand how trends in the price and treatment cost of the originator brand and biosimilar forms of trastuzumab evolved following biosimilar entry. METHODS: We use average…
Source: JCO Oncology PracticeCategories: Hem/Oncs, Latest HeadlinesTweet-
Biosimilar Competition and Payments in Medicare: The Case of Trastuzumab -53% lower prize for Trastuzumab after the introduction of biosimilar.. @JCOOP_ASCO @ASCO https://t.co/UJuVtHsyaK https://t.co/1CtkCILDV3
-
-
Mashup Score: 3Key Clinical Principles in the Management of Glioblastoma - 1 year(s) ago
Glioblastoma is the most common and aggressive primary brain tumor in the adult population and leads to considerable morbidity and mortality. It has a dismal prognosis with average survival of 15-18 months, and the current standard-of-care treatment paradigm includes maximal surgical resection and postoperative concurrent chemoradiotherapy and maintenance chemotherapy, with consideration of Tumor…
Source: JCO Oncology PracticeCategories: Hem/Oncs, Latest HeadlinesTweet-
Key Clinical Principles in the Management of Glioblastoma @JCOOP_ASCO @ASCO https://t.co/0MifiJ5K8k Excellent review by @BrainTumorDoc @Rrkotecha @OncoAlert @JCO_ASCO https://t.co/uLAyQBoTWm
-
-
Mashup Score: 1Toward Achieving Equity in Cancer Clinical Trials - 1 year(s) ago
Unpacking the ACCC-ASCO Implicit Bias Training Program to increase racial and ethnic diversity in clinical trials
Source: JCO Oncology PracticeCategories: Hem/Oncs, Latest HeadlinesTweet-
Welcome, @AvrilColeyMD, to the world of #medtwitter! Avril is an @MGHSurgery resident who will be an incredible academic surgical oncologist for decades to come. Only apt that she published an editorial in @JCOOP_ASCO the same day she joined Twitter! https://t.co/UjYhNTD54t https://t.co/9YuChuItHc
-
-
Mashup Score: 10Role of Immunotherapy in Breast Cancer - 1 year(s) ago
The advent of immunotherapy, particularly immune checkpoint inhibitors (ICIs), has revolutionized the treatment of solid tumor malignancies. In breast cancer, the most robust data to date for ICI exist for triple-negative breast cancer (TNBC). Preclinical studies suggested increased antitumoral immune response in patients with TNBC undergoing ICI treatment. Early clinical trials investigated the…
Source: JCO Oncology PracticeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
RT @jamecancerdoc: Role of Immunotherapy in #breastcancer https://t.co/WGHFLHtLNz @JCOOP_ASCO @JCO_ASCO Excellent review article by @hoper…
-
#JCOOP #BCSM Commentary by Dr. Cesar Santa-Maria: "Where do we go from here with #immunotherapy in #breastcancer? Our foot is in the door...but we need better methods of identifying who actually benefits from ICIs & also understand resistance better" ➡️ https://t.co/yL0pHlxnKc